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Abstract
Background: The aim of the study was to assess the plasma levels of homocysteine in patients
with multiple sclerosis (MS) and to investigate whether an association with depression exists.
Methods:  Plasma homocysteine (Hcy), vitamin B12 and plasma folate were measured in 65
moderately disabled patients with relapsing/remitting MS (RR-MS) and 60 healthy controls. All
subjects were assessed with the Beck Depression Inventory (BDI).
Results: Hcy levels were significantly increased in MS patients compared to controls (13.5 ± 4.7
μmol/l vs 8.5 ± 3.1, p < 0.001). A significant correlation was found between Hcy levels and BDI
scores (Pearson r = 0.3025, p < 0.05). Plasma Hcy was not related to Extended Disability Status
Scale (EDSS) score, age, disease duration or vitamin B12 and folate.
Conclusion: Moderately disabled MS patients with elevated Hcy levels are particularly prone to
develop depressive symptomatology. Further study is warranted in order to elucidate the
prognostic and therapeutic implications of this novel finding.
Background
Homocysteine is a non-essential sulfur-containing amino
acid derived from methionine by demethylation. Vita-
mins B12 and B6 as well as folate play an important role
in the metabolic pathway of homocysteine [1]. A number
of recent studies support the notion that homocysteine
might cause neuronal damage by triggering oxidative
injury and DNA damage [2-5]. As a result, homocysteine
has been implicated in the pathogenesis of numerous
neurodegenerative and psychiatric disorders [1].
Amongst neurological conditions, multiple sclerosis (MS)
has been extensively investigated with regard to homo-
cysteine metabolism, with conflicting results. Some stud-
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ies demonstrated elevated plasma homocysteine (Hcy)
levels in MS patients with [6,7] or without B12 deficiency
[8,9]. By contrast, a single report found no difference in
Hcy levels between MS patients and controls [10].
With regard to psychiatric disorders, depression has been
linked in particular to increased Hcy plasma levels in the
context of altered methylation reactions [11-13]. No
study, however, has attempted to address these two issues
jointly; that is, to investigate plasma homocysteine levels
in patients with MS and depression.
Accordingly, the present study was designed in order to
assess Hcy plasma levels in MS patients and investigate
whether an association with depression and clinical disa-
bility or disease duration exists.
Methods
A total of 65 relapsing remitting MS (RR-MS) patients
with a mean age 39.2 ± 8.3 years, entered the study after
providing informed consent for the procedures. All
patients met the criteria for clinically definite MS accord-
ing to Poser et al. [14], were in remission and had not
received treatment with corticosteroids for at least 2
months prior to their inclusion in the study. The mean
duration of the disease was 9.8 ± 5.9 years and disability
according to Extended Disability Status Scale (EDSS) was
3.2 ± 1.7 points. None of the patients had received B12 or
folate supplementation. All patients included in the study
had normal blood pressure, lipid profile and renal func-
tion and had no risk factors for atherosclerosis.
A total of 60 healthy volunteers with a mean age of 38.2 ±
7.7 years served as a control group. The demographic
characteristics of MS patients and healthy controls are
shown in Table 1.
After overnight fasting, blood samples were drawn from a
peripheral vein and were kept on ice prior to separation
(maximum 30 min after drawing). Total homocysteine
(free plus protein-bound) was quantified using a sand-
wich enzyme immunoassay method based on a mono-
clonal/polyclonal antibody pair (Axis-Shild Diagnostics,
Dundee, UK). Values higher than 15 μmol/l were consid-
ered increased according to relevant literature and manu-
facturer's instructions.
Serum folate and B12 levels were quantified with a para-
magnetic particle chemiluminescence's immunoassay
(Access 2 immunoassay system, Beckman Coulter, Nyon,
Switzerland).
Assessment of depressive symptomatology in all subjects
was performed by the Beck Depression Inventory (BDI)
[15], a self-report screening instrument for depression.
The questionnaire consists of 21 items that measure the
severity of depression in adults scored from 0 to 63. Sub-
jects with BDI scores greater than 13 were characterised as
depressed [16,17]. According to the Goldman consensus
statement on depression in MS, this cut-off level is satis-
factory, in terms of sensitivity and specificity, in ambula-
tory patients with MS and was therefore appropriate in the
context of the present study [16].
Statistics
Statistical testing was performed by Fisher's exact test for
categorical variables whereas an unpaired t test was used
for comparing continuous variables. Correlations
between Hcy levels and other investigated parameters
were derived using Pearson correlation analysis. The level
of statistical significance was set at p = 0.05. All statistical
analyses were performed with SPSS version 10.0 for Win-
dows (SPSS Inc., Chicago, IL, USA).
Results
Plasma Hcy levels were significantly increased in MS
patients compared to controls (13.5 ± 4.7 μmol/l vs 8.5 ±
3.1, p < 0.001; Figure 1A). This increase occurred in the
absence of significant differences in the serum levels of
folate and B12 between MS patients and controls (Figure
1B). Using a cut-off level of 15 μmol/l, MS patients were
further subdivided into those with normal Hcy (values =
15 μmol/l) and patients with increased Hcy (> 15 μmol/
l). MS patients with increased Hcy levels had higher BDI
scores compared to patients with low Hcy, (18.4 ± 14.4 vs
9.3 ± 8.5, respectively, p < 0.05) (Table 2). In addition, the
prevalence of depression was higher in the MS group with
increased Hcy (8 out of 18,44%) compared to patients
with normal Hcy (8 out of 47,17%, p = 0.05).
Pearson correlation analysis showed that BDI was signifi-
cantly associated with Hcy (r = 0.3025, 95% CI = 0.01670
to 0.5426 p < 0.05; Figure 2). By contrast, Hcy concentra-
tions were not significantly related to other investigated
variables (age, disease duration, EDSS, vitamin B12 and
folate) (Table 3).
Table 1: Demographic characteristics of multiple sclerosis (MS) 
patients and controls
RR-MS Controls
No. of subjects 65 60
Age 39.2 ± 8 38.2 ± 7.7
Sex (F/M) 40/25 40/20
Disease duration 9.8 ± 5.9 -
EDSS 3.2 ± 1.8 -
EDSS, Extended Disability Status Scale; Hcy, plasma homocysteine; 
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Discussion
The present study addressed the issue of Hcy metabolism
in MS and investigated whether Hcy levels are related to
depression in this disease. It is concluded that Hcy is
increased in patients with RR-MS without concomitant
signs of vitamin B12 and folate deficiency. In addition, we
report, for the first time, a positive correlation between
increased Hcy levels and depressive symptomatology in
MS patients.
Previous studies regarding Hcy metabolism in MS have
provided contradictory results. With a single exception
[10], these studies concluded that Hcy levels are increased
in MS patients [8,9]. In most cases, however, Hcy
increases were observed in MS patients with vitamin B12
deficiency [7,18,19]. Our results, in agreement with
Vrethem et al. [8] and Ramsaransing et al. [9], indicate that
Hcy increases may occur in MS in the absence of vitamin
B12 and folate deficiency.
Of particular interest is the fact that MS patients with
increased Hcy had higher BDI scores compared to patients
with normal Hcy. From a methodological point of view, it
should be pointed out that BDI, in common with other
depression screening instruments, has certain limitations
in the evaluation of MS patients due to a considerable
overlap between the signs and symptoms of depression
and the signs and symptoms of MS. As a result, BDI may
overestimate depression among patients with somatic
complaints, for instance fatigue [20] which typically
occurs in MS. By contrast, BDI represents a reliable tool
Box and whisker plot of plasma homocysteine (Hcy) and vitamin B12 in multiple sclerosis (MS) patients and controls Figure 1
Box and whisker plot of plasma homocysteine (Hcy) and vitamin B12 in multiple sclerosis (MS) patients and 
controls. Hcy, but not B12 levels, were significantly different amongst the two groups (p < 0.001).
B A
Table 2: Demographic and clinical characteristics of RR-MS 
patients classified according to Hcy levels
Increased Hcy RR-MS Normal Hcy RR-MS
Age 41.8 ± 10.0 * 37.8 ± 7.0
Disease duration 10.7 ± 6.4† 9.621 ± 5.3
EDSS 4.2 ± 2.2† 3.1 ± 1.4
BDI 18.40 ± 14.4§ 9.39 ± 8.3
*p = 0.03; †p = NS; §p = 0.01.
BDI, Beck Depression Inventory; EDSS, Extended Disability Status 
Scale; Hcy, plasma homocysteine; RR-MS, relapsing/remitting MS.
Correlation graph between plasma homocysteine (Hcy) and  Beck Depression Inventory (BDI) scores Figure 2
Correlation graph between plasma homocysteine (Hcy) and 
Beck Depression Inventory (BDI) scores.Annals of General Psychiatry 2008, 7:17 http://www.annals-general-psychiatry.com/content/7/1/17
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with high internal consistency in the evaluation of depres-
sion [21].
Depression occurs frequently during the course of MS and
is multifactorial in origin. It is associated with the degree
of clinical disability, as reflected by the EDSS score [22-24]
and the particular subtype of the disease [25] although
these findings were not replicated in all studies [22,26].
What is particularly relevant to our study is the fact that
severe depression is associated with increased Hcy levels
[27]. A recent population-based study confirmed this link
by showing that subjects with increased Hcy levels are
more likely to suffer from depression [11] while other
studies indicated that folate deficiency and the MTHFR
C677T polymorphism may be causally related to depres-
sion [12,13].
At the biochemical level, the rise in homocysteine levels
observed in patients with depression is ascribed to failure
of methylation of Hcy to methionine due to a shortage of
supply of methyl groups from methyl folate or lack of the
vitamin B12 cofactor for this methylation reaction [27].
Methionine, in turn, is the precursor of S-adenosylme-
thionine, the methyl donor in a host of methylation reac-
tions in the central nervous system (CNS) involving
monoamines and various neurotransmitters, amongst
other cellular constituents. Thus, increased Hcy levels in
depression are thought to reflect functional folate and/or
B12 deficiency, which may ultimately cause an imbalance
at the monoamine or neurotransmitter level.
The mechanism of increased Hcy levels in MS patients,
particularly those with depression, seems to be different
since folate and/or B12 deficiency was not documented in
the context of the present study. Irrespective of the precise
pathogenetic mechanisms, however, increased Hcy may
induce neuronal damage through its neurotoxic action [2-
5]. It is also possible that raised Hcy may accentuate CNS
inflammatory processes by decreasing the production of
apolipoprotein A1 (apoA-I) [28]. ApoA-I is proposed to
display anti-inflammatory properties by interfering with
monocyte-lymphocyte interaction and inhibiting tumour
necrosis factor (TNF)α and interleukin (IL)1β production
[29,30].
The clinical implications of our finding are not entirely
clear. Since Hcy is associated with an atherogenic propen-
sity, MS patients with elevated Hcy and depression might
represent a subgroup of MS patients with a predisposition
for atherothrombotic cerebrovascular disease. In addi-
tion, since our patients were not entered into a treatment
study, it is currently unknown whether vitamin treatment
combined with antidepressants is the optimal way to treat
this subgroup of MS patients.
In conclusion, our results suggest that moderately disa-
bled MS patients with elevated Hcy levels are particularly
prone to develop depressive symptomatology, reflected
by higher BDI scores. Further studies and follow up of this
subgroup of MS patients are warranted in order to eluci-
date the prognostic and therapeutic implications of this
finding.
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